KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Cost of Revenue (2017 - 2025)

Sarepta Therapeutics (SRPT) has 8 years of Cost of Revenue data on record, last reported at $132.3 million in Q4 2024.

  • For Q4 2024, Cost of Revenue rose 199.49% year-over-year to $132.3 million; the TTM value through Dec 2024 reached $319.1 million, up 112.25%, while the annual FY2024 figure was $319.1 million, 112.25% up from the prior year.
  • Cost of Revenue reached $132.3 million in Q4 2024 per SRPT's latest filing, up from $91.7 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $132.3 million in Q4 2024 and bottomed at $12.6 million in Q1 2020.
  • Average Cost of Revenue over 5 years is $38.5 million, with a median of $32.9 million recorded in 2021.
  • Peak YoY movement for Cost of Revenue: fell 16.19% in 2020, then skyrocketed 199.49% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $22.4 million in 2020, then skyrocketed by 41.69% to $31.7 million in 2021, then dropped by 2.98% to $30.8 million in 2022, then soared by 43.43% to $44.2 million in 2023, then soared by 199.49% to $132.3 million in 2024.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $132.3 million in Q4 2024, $91.7 million in Q3 2024, and $44.5 million in Q2 2024.